News summary

Florida Cancer Specialists & Research Institute Accelerates Next Generation of Targeted Cancer Therapies

Source: PR Newswire • Published: 18 Nov 2026, 13:41

Summarized by Masters of Longevity from PR Newswire.

FCS investigators presented first‑in‑human and early clinical trial findings on RAS‑targeted agents.

Florida Cancer Specialists & Research Institute Accelerates Next Generation of Targeted Cancer Therapies
Key Takeaways
  • FCS investigators were involved in first‑in‑human KRAS inhibitor trials.
  • Preliminary phase 1 results were reported for an EGFR‑HER3 bispecific ADC.
  • Statewide partnerships have expanded patient access to early trials.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.